CAMS Blood Diseases Hospital Hematology: Leukemia and Specialist Teams

A Tianjin blood centre, not a general hospital department

This is a specialist blood-disease institution rather than a hematology department inside a general hospital. Its official directory identifies leukemia, red-cell disease, MDS/MPN, lymphoma, pediatric blood disease, thrombosis and hemostasis, transplantation and other services. Their inclusion describes institutional scope, not automatic eligibility or acceptance for an overseas patient.

The hospital's hematology specialty placed second in the Fudan 2023 national specialty reputation list, a historical departmental reference rather than a current ranking of clinicians or subspecialties. More useful for an individual enquiry is the distinction between the documented clinical directions: a leukemia question, a pediatric marrow-failure question and a bleeding-disorder question should not be presented as the same request.

A clear starting point is the diagnosis recorded by the current treating team and the decision the patient wants reviewed. If that diagnosis remains uncertain, say so rather than selecting a team from the hospital's reputation alone. Ask which clinical service should examine the existing information and what further clarification would be needed before it could give an opinion.

Documented clinical subdivisions and what each one handles

Leukemia is a distinct clinical direction, and Wang Jianxiang's official biography identifies leukemia and other hematologic malignancies as his clinical and basic-research focus. For a newly diagnosed or previously treated patient, specify whether the enquiry concerns the diagnosis, an existing treatment proposal or options after earlier care. Ask which part of that question could be reviewed from the available records.

Xiao Zhijian's documented specialist interests include myelodysplastic syndromes, primary myelofibrosis, polycythemia vera, essential thrombocythemia, eosinophilia and rare blood disorders. The hospital's MDS/MPN direction therefore has a different emphasis from a general leukemia enquiry. Include the exact diagnosis used by the current clinicians and ask whether it is the diagnosis itself or the proposed management that needs another opinion.

Zhu Xiaofan's official pediatric profile focuses on childhood leukemia, marrow failure and rare or refractory childhood blood disease. Families can ask how the pediatric service would assess a child's existing records and how any opinion would be shared with the team providing ongoing care. An adult-service description or an academic research interest should not be used to assume a particular pediatric treatment is available.

The thrombosis and hemostasis centre, founded in 1986, documents inherited and acquired bleeding and thrombotic disorders, hemophilia, immune thrombocytopenia, myeloproliferative neoplasms and rare coagulation or platelet disorders. Its work includes consensus and guideline development, an acquired-hemophilia registry and multidisciplinary care. These are distinct clinical and research activities, not a treatment protocol that applies to every patient with an abnormal blood result.

Clinical chief experts and institutional leadership

The checked official clinical biographies identify Wang Jianxiang, Xiao Zhijian and Zhu Xiaofan as clinical chief experts and chief physicians. Wang directs the National Clinical Research Center for Blood Diseases; Xiao is its deputy director. Wang and Zhu are also identified as doctoral supervisors. Those research and clinical roles describe different responsibilities, rather than interchangeable titles for the hospital director.

A chief-expert designation is not confirmation that the named clinician will personally accept an overseas case. Ask who would be responsible for reviewing the file and how the opinion would be communicated. For a child, confirm that the enquiry is being assessed through the pediatric service rather than assuming an adult specialist's field transfers directly to pediatric care.

Peking Union Medical College's academic biography separately identifies Cheng Tao as director of the hospital and Institute of Hematology and of the Blood and Health national key laboratory. His leadership and research profile helps describe the institution's academic setting; it does not establish a personal appointment or make him the treating specialist for every blood disorder.

Research that shapes the questions patients can ask

Cheng Tao's documented research concerns hematopoietic stem-cell biology, cell potency and blood-cell ecosystems. The academic profile lists work on regulation and regeneration, including studies of transplanted-cell differentiation and cell behaviour. These are basic and translational research questions. A publication, patent or laboratory platform must be distinguished from a treatment that is approved, available and appropriate for a particular person.

The thrombosis and hemostasis centre describes drug and gene-therapy studies alongside its clinical work. Someone interested in a research-related intervention should ask about the specific product or protocol, its regulatory and clinical status, and whether the hospital can assess eligibility. A general description of research cannot settle those questions, and no trial place or access to a therapy is promised here.

The directory also names transplantation, immunocellular therapy, regenerative medicine and a research ward. When any of these terms appears in a proposed plan, ask what it means in that plan: an established clinical procedure, an investigational intervention, or a scientific research interest. The distinction should be explained for the actual condition rather than inferred from a department name or an achievement reported in the news.

Honours, attributed to the right people and the right dates

Wang Jianxiang's profile lists national health-authority recognition for an outstanding young and middle-aged contributor, a State Council special allowance and PUMC tenured professorship. Xiao Zhijian's includes the 2020 Tianjin Model Worker designation and National Outstanding Science and Technology Worker recognition, alongside a PUMC tenured professorship. No years are added to honours where the checked biographies do not supply them.

Zhu Xiaofan's profile records a Tianjin Natural Science First Prize, Wuzhou Women Science and Technology recognition and a Song Qingling pediatric medical award. The thrombosis and hemostasis centre lists a 2009 National Science and Technology Progress Second Prize, a 2022 Tianjin Natural Science Special Prize and a 2023 Tianjin Science and Technology Progress First Prize. These centre-level honours are not attributed here to an unspecified individual or project.

Cheng Tao's academic profile records, as first contributor, the 2020 National Natural Science Second Prize for hematopoietic stem-cell regulation and regeneration strategies. It also lists the 2023 National Innovation Pioneer recognition and 2024 Wu Jieping–Paul Janssen award. These attributable achievements describe academic contributions; they are separate from the clinical assessment needed to choose a team or consider a treatment.

Practical decisions before an overseas referral

Frame the enquiry around one unresolved decision. Is the request for review of the working diagnosis, comparison of proposed approaches, or clarification after previous treatment? A summary can identify the question and the records already available. Ask which pathology, marrow, laboratory or treatment documents the receiving service actually requires, in what format and with what translation, rather than commissioning new tests from a generic list.

Before travelling, confirm what can be discussed from records and what requires assessment in person. Ask who would provide the opinion, how interpretation and consent discussions would be handled, and how recommendations could be communicated to the doctors at home. Confirm the scope and charges in writing. Neither a preliminary enquiry nor a departmental profile confirms admission, a named appointment or a treatment offer.

How ChinaSpecialistCare can fit into this decision

ChinaSpecialistCare can help organise a focused hematology enquiry, prepare the records requested for review and coordinate appointment and interpretation arrangements where available. We work independently of the hospital, without promising acceptance, a particular clinician or therapy. An initial enquiry is free; clinical suitability and the next steps remain the treating hospital's decisions.

Blood disorder and blood cancer care